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Abstract
Long-term-care facilities (LTCFs) are reservoirs of resistant bacteria. We undertook a point-prevalence survey and risk factor analysis
for speciﬁc resistance types among residents and staff of a Bolzano LTCF and among geriatric unit patients in the associated acute-care
hospital. Urine samples and rectal, inguinal, oropharyngeal and nasal swabs were plated on chromogenic agar; isolates were typed by
pulsed-ﬁeld gel electrophoresis; resistance genes and links to insertion sequences were sought by PCR; plasmids were analysed by PCR,
restriction fragment length polymorphism and incompatibility grouping. Demographic data were collected. Of the LTCF residents,
74.8% were colonized with ‡1 resistant organism, 64% with extended-spectrum b-lactamase (ESBL) producers, 38.7% with methicillin-
resistant Staphylococcus aureus (MRSA), 6.3% with metallo-b-lactamase (MBL) producers, and 2.7% with vancomycin-resistant entero-
cocci. Corresponding rates for LTCF staff were 27.5%, 14.5%, 14.5%, 1.5% and 0%, respectively. Colonization frequencies for geriatric
unit patients were lower than for those in the LTCF. Both clonal spread and plasmid transfer were implicated in the dissemination of
MBL producers that harboured IncN plasmids bearing blaVIM-1, qnrS, and blaSHV-12. Most (44/45) ESBL-producing Escherichia coli isolates
had blaCTX-M genes of group 1; a few had blaCTX-M genes of group 9 or blaSHV-5; those with blaCTX-M-15 or blaSHV-5 were clonal. Risk fac-
tors for colonization of LTCF residents with resistant bacteria included age ‡86 years, antibiotic treatment in the previous 3 months,
indwelling devices, chronic obstructive pulmonary disease, physical disability, and the particular LTCF unit; those for geriatric unit
patients were age and dementia. In conclusion, ESBL-producing and MBL-producing Enterobacteriaceae and MRSA were prevalent among
the LTCF residents and staff, but less so in the hospital geriatric unit. Education of LTCF employees and better infection control are
proposed to minimize the spread of resistant bacteria in the facility.
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Introduction
Resistant bacteria are a major public health concern. Current
problems include Enterobacteriaceae with extended-spectrum-
b-lactamases (ESBLs), derepressed or acquired AmpC cepha-
losporinases and metallo-b-lactamases (MBLs), and also
methicillin-resistant Staphylococcus aureus (MRSA) and vanco-
mycin-resistant enterococci (VRE). These organisms are
most often discussed in the context of hospital infection, but
are also important in long-term-care facilities (LTCFs), where
they have been associated with increased morbidity, mortal-
ity and cost [1]. Colonized LTCF residents may act as vec-
tors for the transfer of resistant bacteria into acute-care
hospitals, where these may cause infection in their initial
host or spread to other vulnerable patients. Donskey found
that 15% of hospitalized patients colonized with resistant
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Gram-negative bacteria subsequently developed a bactera-
emia due to the same strain [2].
Enterobacteriaceae with ESBLs, AmpC enzymes or MBLs
are widely seen in clinical samples by the microbiology
laboratory in Bolzano, Italy, as are MRSA strains, whereas
VRE are rarer. Except for VRE, these organisms are
recorded more frequently from LTCF residents than from
acute-care hospital patients (R. Aschbacher, unpublished
data). Such observations are, however, prone to sampling bias.
To test their broader validity, we undertook a point-
prevalence study of key resistant pathogens in residents and
staff of the LTCF attached to the hospital and in patients of
two of the hospital’s geriatric units. Particular attention was
paid to MBL-producing and ESBL-producing Enterobacteriaceae,
as these have caused clinical problems in the hospital [3].
Materials and Methods
Facility, patient characteristics, and survey design
In October 2008, we conducted a point-prevalence study
concerning MRSA, VRE and of Enterobacteriaceae with ESBLs,
MBLs or high-level AmpC activity in the 120-bed LTCF
attached to the regional hospital in Bolzano, a city of 100 000
people in northern Italy. All residents of all ﬁve LTCF units
were eligible to participate, and the study was approved by
the Ethics Committee of the Bolzano Teaching Hospital.
Informed written consent was obtained from the residents
or, if they were unable to consent, from their relatives. LTCF
staff members were also screened. A parallel 1-day point-
prevalence study was performed involving all patients hospi-
talized in two of the three 24-bed units of the geriatric ward
of the acute-care hospital, again with the patients’ written
consent. The third unit was excluded, as it mostly serves can-
cer patients with advanced disease. The LTCF and geriatric
unit staff move frequently among the various units, but not
between the LTCF and the acute-care hospital.
Microbiological methods
To assess carriage of resistant bacteria, midstream or cathe-
ter urine samples and rectal, inguinal, oropharyngeal and
nasal swabs from all participants were spread on ChromID
ESBL, MRSA and VRE agars (bioMe´rieux, Marcy l’Etoile,
France). The formulations of these media are proprietary,
but ChromID ESBL is cefpodoxime-based and allows the
growth of bacteria with cephalosporin resistance mechanisms
other than ESBL production [4]; ChromID MRSA contains
cefoxitin (4 mg/L) and ChromID VRE has vancomycin (8 mg/
L). The ESBL plates were incubated for 18–24 h at 35C,
whereas the MRSA and VRE plates were incubated for 48 h.
Gram-negative bacteria were subcultured on MacConkey
agar, and Gram-positive bacteria on colistin–nalidixic acid
sheep blood agar. The subcultured isolates were re-identiﬁed
and tested for antibiotic susceptibility in the hospital’s
clinical microbiology laboratory, using the Vitek 2 System
(bioMe´rieux), calibrated against CLSI susceptibility criteria
[5]. AST-GN015 susceptibility cards, with a direct ESBL test,
were used for Gram-negative bacteria, AST-GP049 cards,
with both oxacillin and cefoxitin, for MRSA, and AST-GP034
cards for enterococci. Phenotypic identiﬁcation of b-lactam-
ase types among the isolates growing on ChromID was
based on the Vitek 2 results and those of b-lactamase-diag-
nostic Etests (cefotetan/cefotetan + cloxacillin for AmpC; im-
ipenem/imipenem + EDTA for MBLs; and cefotaxime/
cefotaxime + clavulanate, ceftazidime/ceftazidime + clavula-
nate and cefepime/cefepime + clavulanate for ESBLs; all three
were from AB Biodisk, Solna, Sweden). In addition, Hodge/
clover leaf plates were used for carbapenem-resistant iso-
lates [6]. VRE were also conﬁrmed by Etest, and equivocal
MRSA isolates were tested for penicillin-binding protein 2¢,
using latex agglutination (Slidex MRSA Detection; bio-
Me´rieux). MICs for MBL producers and ESBL-producing
E. coli isolates were reconﬁrmed by agar dilution, performed
according to BSAC guidelines [7].
Molecular methods
Isolates were typed using pulsed-ﬁeld gel electrophoresis
(PFGE) of XbaI-digested genomic DNA [8], with banding
patterns analysed using Bionumerics software (Applied
Maths, Sint-Martens-Latem, Belgium); they were considered
to be clonally related if there was ‡85% similarity in proﬁle
[9].
Multiplex PCR for blaCTX-M genes was performed with
published primers [10]. Isolates with MBL phenotypes were
tested by PCR with consensus primers for blaVIM-1/2 [11] and
blaVIM-1 [12]. Published primers were also used to seek qnrA
[13], qnrB [14] and qnrS [15] alleles and blaSHV genes [16].
Sequencing of PCR products derived from blaVIM and qnrS
was performed with the same primers used for ampliﬁcation.
For blaSHV, primers SHV-c (ATGCGTTATATTCGCCTGTG)
and SHV-d (CTTAGCGTTGCCAGTGCTCG) were used,
together with other previously described primers [16]. CTX-
M group 1 genes were ampliﬁed with the primers CTX-
M1orfF (PROM+) and CTX-MorfR (PRECTX-M-3-B) [17],
and CTX-M group 9 genes with primers CTX-M 9A and
CTX-M 9C [18]; sequencing was performed using the same
primers together with published internal primers [10]. Pub-
lished primers were used to amplify the IS26 insertion ele-
ment and to investigate linkage of blaCTX-M genes of group 1
with ISEcp1 and IS26 [19]. In all cases, products were ﬁrst
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puriﬁed with the Geneclean Turbo for PCR Kit (Q-BIOgene,
Cambridge, UK), with sequencing by the GenomeLab Dye
terminator Cycle Sequencing system, using the Quick Start
Kit (Beckman Coulter, High Wycombe, UK) with a Beckman
Coulter CEQ 8000 Genetic Analysis System.
Mega X E. coli DH10B T1 electrocompetent cells (Invitro-
gen, Paisley, UK) were transformed by electroporation with
a Bio-Rad Gene-Pulser II at 2.0 kV, 200 W and 25 lF, using
plasmids extracted by the method of Kado and Liu, and
precipitated twice with ethanol [20]. Transformants were
selected on Luria–Bertani agar containing cefotaxime (2 mg/
L). Plasmids bearing blaVIM-1 were extracted from transfor-
mants and digested with HpaI (Promega, Southampton, UK)
and BamHI/SacI (Roche, Mannheim, Germany). The resulting
fragments were separated by electrophoresis on 1% agarose.
Plasmid typing was by PCR (inc/rep PCR) for the major
incompatibility groups [21]. Phylogenetic groups of E. coli
were determined by PCR [22].
Epidemiological investigation and statistical analysis
To examine risk factors for colonization with resistant
organisms, in-house physicians reviewed hospital records
and, using an Epi Info questionnaire, recorded demographic
data as follows: patient age, gender, length of stay in the
LTCF or geriatric ward, diagnosis at admission, Barthel
immobility score, comorbidities (dementia, urinary
incontinence, diabetes, cancer, vascular diseases, chronic
obstructive pulmonary disease, decubitus ulcers and immu-
nosuppressive therapy), and indwelling medical devices (uri-
nary catheters, percutaneous enteral gastrostomy tubes,
tracheostomy tubes and nasogastric tubes). For the LTCF
patients, the hospital ward of the previous acute admission,
antibiotic treatments in the preceding 3 months and other
possible risk factors (urinary incontinence, decubitus ulcers
and immunosuppressive therapy) were also recorded. For
statistical analysis, three groups of subjects were deﬁned:
(i) LTCF residents; (ii) LTCF staff; and (iii) geriatric unit
patients. Associations were investigated using the chi-
square test or Fisher’s exact method. Group-speciﬁc mean
ages were compared by the generalized linear model pro-
cedure, after testing for homoschedasticity of variances
with Levene’s test. In the case of heteroschedasticity,
Welch’s test was performed. Logistic regression analyses
were developed to investigate colonization with resistant
bacteria in general and ESBL producers and MRSA in par-
ticular, ﬁrst as univariate and then as multivariate models
through stepwise selection. Analyses were performed using
the SAS statistical package, release 9.1.3, and with Epi Info
v. 3.5.
Results
Epidemiological investigation
Among 120 LTCF residents present in October 2008, 111
(92.5%) agreed to participate in the point-prevalence survey;
among staff members, 69 of 79 (87.3%) agreed to participate,
mainly nurses and physicians. Sixty-one (55.0%) of the partici-
pating residents were women, with a median age of 84 years
(range 22–96 years); the median age of the 50 male residents
was 77 years (range 22–94 years). The median length of
LTCF stay was 21 months (range: <1–96 months). The most
recent hospital admission of 36 of the 111 participating LTCF
residents was to one of the two acute-care geriatric units
that were also surveyed. Forty-ﬁve of the 48 geriatric unit
patients also agreed to participate in the investigation:
32 (71.1%) were women (median age 85 years, range
75–97 years) and 13 were men (median age 79 years, range
74–91 years); none was ordinarily a resident in the LTCF.
The isolation frequencies for the various resistance types
in different patient groups are shown in Table 1. Among the
LTCF residents, 74.8% (83/111) were colonized with at least
one resistant organism, and 31.5% (35/111) with at least
two. ESBL-producing Enterobacteriaceae, together with MRSA
strains, were isolated from 28.8% (32/111), and at least two
different ESBL-producing enterobacterial species from 21.6%
(24/111). Twenty-seven of 111 LTCF residents, two of 69
LTCF staff members and two of 45 geriatric unit patients
were also colonized with Acinetobacter baumannii (which
grew on the ESBL ChromID agar), but none of these isolates
was resistant to carbapenems, and they were not studied
further. Similarly, colonization with Pseudomonas aeruginosa
was not investigated.
ESBL-producing Enterobacteriaceae and, more surprisingly,
MRSA isolates were most often recovered from rectal sam-
ples. The best combinations of screening measures to recog-
nize patients colonized with key resistant bacteria were a
rectal swab and a urine sample for ESBL producers, and both
inguinal and oropharyngeal swabs for MRSA (Table 2). Test-
ing only nasal swabs would have resulted in substantial
underestimation of colonization with MRSA.
MICs for, and molecular typing of, MBL-producing strains
Ten MBL-producing isolates were found; eight from LTCF
residents (one with two different producers), one from a staff
member, and one from a geriatric unit patient (Table 3). All
had blaVIM-1 together with qnrS. The PFGE patterns of two
blaVIM-positive Klebsiella oxytoca isolates from LTCF residents
were identical, whereas the patterns of the two MBL-produc-
936 Clinical Microbiology and Infection, Volume 16 Number 7, July 2010 CMI
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ing E. coli isolates from LTCF residents and the one from a
staff member were >80% related. All three E. coli isolates
belonged to phylogenetic group B2. MICs of imipenem for
the MBL producers ranged from 2 to 16 mg/L, and were
reduced to £0.5 mg/L in the presence of 320 mg/L EDTA,
except in the case of Morganella morganii and Providencia
stuartii isolates—species that are inherently less susceptible to
imipenem. MICs of meropenem and ertapenem for the MBL
producers generally were lower than those of imipenem, but
above those for MBL-negative isolates. MICs of ciproﬂoxacin
ranged from 1 to >8 mg/L. Two MBL producers were highly
susceptible to aztreonam, with MICs £0.25 mg/L, whereas
the aztreonam MIC for the P. stuartii isolate was 4 mg/L;
values were ‡64 mg/L for the other seven isolates. Five of
the seven aztreonam-resistant MBL producers, excluding only
the two Klebsiella pneumoniae isolates, were examined by
TABLE 1. Long-term-care facility
(LTCF) residents, staff and geriat-
ric unit patients colonized with
bacteria of various resistance types Bacteria and resistance type
Screening samples; % colonized
LTCF residents vs.
geriatrics unit patients:
p-value of differences
LTCF
(residents),
n = 111
LTCF
(staff),
n = 69
Geriatrics unit
(patients),
n = 45
All resistance groups 74.8 27.5 22.2 <0.0001
All enterobacteria, ESBL-positivea 64.0 14.5 8.9 <0.0001
Escherichia coli, ESBL-positive 41.4 11.6 6.7 <0.0001
Proteus mirabilis, ESBL-positive 24.3 1.5 2.2 <0.0001
Klebsiella pneumoniae, ESBL-positive 11.7 1.5 0.034
Morganella morganii, ESBL-positive 7.2 2.2 0.45
Citrobacter koseri, ESBL-positive 3.6
Klebsiella oxytoca, ESBL-positive 1.8
Enterobacter cloacae, ESBL-positive 0.9
Serratia fonticola, ESBL-positive 1.5
All enterobacteria, MBL-positive 5.4b 1.5 2.2 0.67
E. coli, MBL-positive 1.8 1.5
K. pneumoniae, MBL-positive 1.8
K. oxytoca, MBL-positive 1.8
Citrobacter freundii, MBL-positive 2.2
All enterobacteria, high-level AmpC 4.5 1.5 6.7 0.69
E. cloacae, high-level AmpC 3.6 2.2 1.0
E. coli, high-level AmpC 0.9 2.2 0.49
Serratia marcescens, high-level AmpC 2.2
Hafnia alvei, high-level AmpC 1.5
MRSA 38.7 14.5 6.7 <0.0001
VREc 2.7 0.56
ESBL, extended-spectrum b-lactamase; MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant
enterococci.
aEnterobacteria producing both an ESBL and an MBL are included in both totals.
bUrine sample of one further patient tested positive for two MBL-producing enterobacterial species (Providencia
stuartii, M. morganii) shortly before the screening period; inclusion of these samples brings the MBL-positive rate to
6.3% (7/111).
cAll three VRE were Enterococcus faecalis.
TABLE 2. Percentages of patients,
residents or staff found to be
positive for methicillin-resistant
Staphylococcus aureus (MRSA) or
extended-spectrum b-lactamase
(ESBL) producers with various
specimen type combinations
MRSA (%) ESBL producers (%)
All study
populations pooled
LTCF
residents
All study
populations pooled
LTCF
residents
Rectal 61a 69 96 95
Inguinal 59 67 73 82
Oropharyngeal 53 50 35 40
Nasal 48 45
Urine 23 43
Rectal + inguinal 75 86 97 97
Rectal + oropharyngeal 77 81 96 95
Rectal + nasal 80 81
Rectal + urine 99 98
Inguinal + oropharyngeal 82 88 73 82
Inguinal + nasal 80 81
Inguinal + urine 80 91
Oropharyngeal + nasal 77 69
Oropharyngeal + urine 60 68
LTCF, long-term-care facility.
aProportion of all positives with the group detected by indicated sample type.
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PCR and found to be positive for blaSHV. One blaVIM-1-positive
E. coli isolate (aztreonam MIC >64 mg/L) also had a blaCTX-M
gene belonging to group 1. Except for the P. stuartii isolate,
the MBL-positive isolates had high-level resistance to oxyimi-
no-cephalosporins (‡32 mg/L) and cefoxitin (‡32 mg/L), with
weak synergy, at most, with clavulanate, generally reducing
the cephalosporin MIC £4-fold.
Three MBL producers from LTCF residents (E. coli 6,
K. oxytoca 105, and M. morganii 445) were used as plasmid
donors for successful transformation of E. coli DH10B. All of
the transformants were PCR-positive for blaVIM-1, qnrS,
and blaSHV, and contained plasmids designated pECO6,
pKOX105.1, and pMMO445, respectively. We also obtained
a transformant with a derivative plasmid pKOX105.2 from
K. oxytoca 105; this carried blaVIM-1 but lacked qnrS and
blaSHV. The transferred plasmids pECO6 and pKOX105.1
(Fig. 1, lanes 1 and 2) were identical by digestion with HpaI
(and BamHI/SacI; data not shown) and very similar to
pKOX105.2 and pMMO445 (Fig. 1, lanes 3 and 4). All of the
plasmids belonged to incompatibility group IncN.
MICs of, and molecular typing of, ESBL-producing E. coli
isolates
Forty-two of 46 ESBL-producing E. coli isolates from LTCF
residents, all eight from staff members and all three from the
geriatric unit patients were tested further. In all cases, MICs
were ‡2 mg/L for at least one of cefotaxime, ceftazidime or
cefpirome (Fig. 2), and were reduced eight-fold or more in
the presence of clavulanate (4 mg/L) whereas cloxacillin
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FIG. 1. Plasmids extracted from Escherichia coli DH10B transformants,
digested with HpaI and separated on a 0.7% agarose gel: pECO6
(lane 1), pKOX105.1 (lane 2), pKOX105.2 (lane 3) and pMMO445
(lane 4) were from isolates collected in the surveillance of long-
term-care facility residents. Lane M has molecular weight markers.
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FIG. 2. Pulsed-ﬁeld gel electrophoresis (PFGE) dendrogram of the extended-spectrum b-lactamase (ESBL)-producing Escherichia coli isolates from
the screening of the long-term-care facility (LTCF) residents (R) and staff members (S) and geriatric unit patients (G). Speciﬁc LTCF unit, ESBL
type, cefotaxime (CTX) and ceftazidime (CAZ) MICs, the presence of IS26 adjacent to blaCTX-M-group-1 (‘IS26 link’), presence of qnrS and phylo-
genetic group are shown as A1, A2, B, C or D. PFGE clusters with >85% similarity are indicated. NA, not applicable; ND*, ESBL type not
determined (SHV-negative and CTX-M negative); NT**, not typeable by the PCR method.
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(100 mg/L) had no signiﬁcant effect. All were resistant to
ampicillin and piperacillin, whereas amoxicillin–clavulanate
(2 : 1) MICs varied between 8 and 32 mg/L. All but three
(E. coli R35, S168 and S183 with MICs £0.125 mg/L) were
substantially resistant to ciproﬂoxacin, with MICs ‡8 mg/L,
whereas the MICs of aminoglycosides were bimodally distrib-
uted, with 23 of 53 isolates being susceptible to tobramycin
(4 mg/L) and 28 of 53 being resistant at ‡32 mg/L; 37 of 53
were susceptible to gentamicin (4 mg/L) and 15 of 53 were
resistant at ‡32 mg/L and 39 of 53 were susceptible to ami-
kacin (8 mg/L), but 14 of 53 were resistant at ‡16 mg/L. All
remained susceptible to imipenem (0.5 mg/L), meropenem
(0.06 mg/L), ertapenem (1 mg/L), tigecycline (1 mg/L) and
colistin (1 mg/L).
PFGE deﬁned clusters A1, A2, B, C and D among 52 ESBL-
producing E. coli isolates (one isolate was not typeable).
Cluster A1 contained four blaSHV-5-positive isolates, whereas
two further isolates with this enzyme formed cluster D. All
but one of these blaSHV-5-positive isolates were from residents
of LTCF unit 5; the exception was from a staff member. Clus-
ters A2 and C contained 18 isolates with blaCTX-M genes of
group 1 (one gene from each cluster was sequenced and iden-
tiﬁed as blaCTX-M-15), all with cefotaxime MICs >256 mg/L and
ceftazidime MICs generally ‡64 mg/L. Another 14 isolates
with blaCTX-M genes of group 1(one identiﬁed by sequencing
as blaCTX-M-15) formed cluster B: cefotaxime and ceftazidime
MICs for these were £128 mg/L and £32 mg/L, respectively,
and PFGE patterns closely resembled that of UK strain A [19].
Two unique isolates had CTX-M-14-like enzymes, on the basis
of partial sequencing and distinct PFGE patterns, whereas one,
also with a unique PFGE pattern, had blaCTX-M-1 with insertion
of ISEcp1 80 bp upstream. One ESBL-positive isolate had only
blaTEM: cefotaxime and ceftazidime MICs for this isolate were
2 mg/L, decreasing to £0.25 mg/L in the presence of clavula-
nate; we did not seek to identify its enzyme.
PCR for the linkage of blaCTX-M genes of group 1 with
upstream ISEcp1 gave an approximately 600-bp fragment for
isolates in clusters A2 and C, and sequencing revealed an
ISEcp1-like element 48 bp upstream of the b-lactamase start
codon. A slightly larger fragment was seen in strain G183,
which had blaCTX-M-1, whereas all 14 isolates belonging to
cluster B had IS26 upstream of blaCTX-M genes of group 1, as
in UK strain A [19]. Only four of the cluster B isolates gave
ampliﬁcation products in the linkage assay for ISEcp1and
blaCTX-M genes of group 1, all with a fragment length com-
patible with insertion of IS26 in the inverted repeat sequence
of ISEcp1, as in UK strain A [19]; the other ten cluster B
isolates did not give a PCR product. Eight ESBL-positive
blaVIM-negative isolates had qnrS; six of these belonged to
cluster B, and none had qnrA or qnrB.
Risk factors for colonization
Colonization of LTCF residents with resistant organisms,
including ESBL producers and MRSA, was associated with
several risk factors in univariate and multivariate analysis
(Table 4). Age >86 years was an independent risk factor for
ESBL producers among LTCF residents, as was administra-
tion of antibiotics within the previous 3 months. An associa-
tion with previous antimicrobial treatment was marginally
signiﬁcant for MRSA (OR 2.31; 95% CI 1.00–5.34; p 0.050);
prior treatment with ﬂuoroquinolones was speciﬁcally associ-
ated with MRSA colonization in univariate analysis only. Uni-
variate analysis also revealed that the presence of any
invasive medical device was a signiﬁcant risk factor for colo-
nization with resistant bacteria, ESBL producers or MRSA,
and indicated an association between colonization with ESBL
producers and the presence of a percutaneous enteral gas-
trostomy tube, tracheostomy tube or indwelling urinary
catheter, and also between colonization with resistant bacte-
ria and a urinary catheter. MRSA colonization was weakly
associated with a nasogastric tube (OR 8.82, 95% CI 0.99–
78.3, p 0.051). Chronic obstructive pulmonary disease was
an independent risk factor for MRSA, but the most signiﬁcant
risk factor for MRSA, ESBL producers and all resistant bacte-
ria in LTCF residents was chronic immobility, based on a
Barthel index score of 0.
Being resident in unit 1 of the LTCF was associated with
signiﬁcantly less colonization by all resistant bacteria, ESBL
producers and MRSA; residence in unit 3 was associated
with signiﬁcantly lower carriage of ESBL producers and
MRSA than residence in the other three LTCF units. Of the
eight MBL-producing Enterobacteriaceae from LTCF residents,
ﬁve (from four residents) were from unit 4, two were from
unit 2 and one was from unit 5, whereas four of the ﬁve
Enterobacteriaceae with high-level AmpC production were
isolated from residents in unit 4 and one was isolated from a
resident in unit 5. The three VRE—all Enterococcus faecalis
with the VanA phenotype—were from patients in units 3, 4
and 5. Dementia without chronic immobility was associated
with a reduced risk for colonization with ESBL producers
and all resistant bacteria in the univariate but not in the mul-
tivariate analysis, and this may explain the lower resistance
rates in LTCF unit 1, which cares for residents with the
behavioural and psychological symptoms of dementia (agita-
tion/aggression, delusions, anxiety, aberrant motor behaviour,
hallucinations, etc.).
Age ‡86 years was also a risk factor for colonization
with all resistant bacteria in the geriatric units (Table 5);
here, however (and in contrast to the LTCF), dementia
was a positive risk factor for colonization with all resistant
bacteria.
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Discussion
We evaluated colonization with resistant bacteria among res-
idents of a LTCF and two linked geriatric units of the acute-
care hospital in Bolzano. Overall, 74.8% of LTCF residents
were colonized with at least one target organism, most
frequently an ESBL producer (64.0%), MRSA (38.7%), MBL
producer (6.3%) or AmpC hyperproducer (4.5%). VRE colo-
nization was rare (2.7%). Many residents had more than one
target organism, underscoring the role of LTCFs as a reser-
voir for these organisms [1,23,24]. MRSA colonization among
LTCF residents has long been recognized, sometimes with
colonization frequencies ‡50% [1,24,25].
Carriage of Enterobacteriaceae with VIM MBLs by 6.3% of
LTCF residents is of special concern: MBL-producing Entero-
bacteriaceae are rare in Europe, except for Greece [26],
where plasmids encoding the VIM-1 enzyme have spread
among K. pneumoniae strains [27]. An Italian countrywide
survey in 2004 identiﬁed only one MBL producer (an Enterob-
acter cloacae isolate) among over 12 000 Enterobacteriaceae
screened [28], with further recent single isolates [29] or
clusters being found in Genoa [30] and Bolzano [3]. The
present data imply: (i) resident-to-resident transfer of MBL
producers in the LTCF, on the basis of identical or similar
PFGE patterns for a pair of K. oxytoca isolates and for three
E. coli isolates, one of them from a staff member; and (ii)
strain-to-strain plasmid transfer, on the basis of identical or
related IncN plasmids with blaVIM-1 and qnrS in multiple
Enterobacteriaceae species. The plasmids from the LTCF resi-
dents’ isolates had very similar restriction patterns to clinical
strains collected up to 3 years previously [3].
Many colonizing Enterobacteriaceae had ESBL genes: princi-
pally, blaCTX-M genes of group 1 (81%), blaCTX-M-14 (4%) and
blaSHV-5 (13%). The host isolates of these genes included four
major clusters as determined by PFGE, designated A1, A2, B
and C. Cluster B isolates resembled the UK strain A, an
ST131 variant, in: (i) PFGE proﬁle (Fig. 2); (ii) having an IS26
element upstream of blaCTX-M-15; and (iii) antibiogram, with
lower-level cephalosporin resistance, probably contingent on
the separation of blaCTX-M-15 from its usual promoter in
ISEcp1 [19]. Strain A is widespread in the UK and was previ-
ously identiﬁed from a patient in Austria who had visited
southern Italy but not the UK [31]. All three MBL-producing
E. coli isolates and 90% of ESBL-producing E. coli isolates
belonged to phylogenetic group B2, whereas 3.8% of the
ESBL producers belonged to group D. These phylogenetic
groups—particularly B2—account for most virulent extra-
intestinal strains of the species [22].
LTCF outbreaks of E. coli with CTX-M-15 (the common-
est group 1 type) were reported in 2000–2002 in Canada
[32], and a survey in northern Italy in 2006–2007 revealed
them in 9.1–100% of urine samples from LTCF residents
with indwelling catheters [33].
Movement of patients and staff between the LTCFs and
hospitals may facilitate dissemination of resistant bacteria. It is
unclear whether most de novo acquisition occurs in the LTCF
or during occasional hospitalizations [1], but the lower colo-
nization rates among the geriatric unit patients argue against
the hospital as the main source, as does the fact that, during
TABLE 5. Univariate and multivari-
ate logistic regression analysis of
risk factors associated with coloni-
zation of geriatric unit patients
with resistant bacteriaVariable
45 Patients
(%)
Colonization with resistant bacteria of any or of the
types studieda
Univariate analysis Multivariate analysis
OR (95% CI) p-value OR (95% CI) p-value
Male sex 28.9 0.55 (0.10–3.00) 0.48
Age ‡86 years 37.8 3.27 (0.78–13.9) 0.11 6.84 (1.11–42.3) 0.039
Antibiotics in last 3 months 33.3 2.5 (0.59–10.5) 0.21 5.68 (0.62–34.9) 0.061
Fluoroquinolones 26.7 1.19 (0.11–12.8) 0.89
Penicillins 46.7 1.5 (0.24–9.22) 0.66
Cephalosporins 26.7 1.19 (0.11–12.8) 0.89
Dementia 33.3 4.33 (0.99–18.9) 0.051 9.52 (1.47–61.8) 0.018
Peripheral vascular disease 80 2.67 (0.29–24.3) 0.38
Incontinence 57.8 1.97 (0.44–8.87) 0.38
Diabetes 24.4 0.28 (0.03–2.49) 0.25
Cancer 24.4 0.72 (0.13–4.05) 0.71
Decubitus ulcer 8.9 4.13 (0.50–33.9) 0.19
Chronic obstructive
pulmonary disease
17.8 0.44 (0.05–4.12) 0.47
Any medical device 22.2 1.67 (0.39–7.19) 0.49
Urinary catheter 28.9 1.07 (0.23–4.99) 0.93
Nasogastric tube 2.2 ND ND
ND, not deﬁned.
aSee listing in Table 4.
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2008, the prevalence of ESBL producers among routine clini-
cal isolates from LTCF residents far exceeded that among
geriatric unit patients (40% vs. 9%; p <0.0001). A striking fea-
ture was the colonization of 27.5% of LTCF staff with resis-
tant bacteria: 14.5% with ESBL producers, 14.5% with MRSA,
and one nurse with a blaVIM-1-positive E. coli strain. This
carriage probably reﬂects resident-to-staff and, perhaps, staff-
to-staff transmission. Elsewhere, MRSA colonization rates of
LTCF staff of 7.5–22.7% [34,35] have been reported.
Risk factors found here for colonization with ESBL pro-
ducers in LTCF residents included treatment with antibiotics
within the preceding 3 months, whereas invasive medical
devices were associated with both ESBL producers and
MRSA. These ﬁndings support published data: prior antibiotic
treatment is a well-recognized risk factor for colonization
with resistant organisms [25], including ESBL producers [1]
and MRSA [24], whereas invasive medical devices are consid-
ered to be important for ESBL producers [36] and MRSA
[24,25]; chronic obstructive pulmonary disease was found to
be an independent risk factor for MRSA colonization among
LTCF residents in our study and by others [37]. However,
the most important risk factor for carriage of resistant
organisms, ESBL producers and MRSA was the particular
LTCF unit of residence. This is explicable, because the ﬁve
units manage residents with different levels of independence,
basal disease, comorbidity and functional status, all of which
inﬂuence the frequency and nature of staff contact. Residents
in LTCF units 2 and 5 are non-ambulatory and require
extensive assistance with daily living activities, along with
nursing and medical care; those in units 3 and 4 have less
functional disability or comorbidity; and those in unit 1 have
dementia but are ambulatory. The large number of ambulant,
and relatively autonomous, residents in unit 1 may explain
the inverse association between dementia and resistant
bacteria found here. A converse, positive, association
between resistant bacteria and dementia in the geriatric units
possibly indicates acute events leading to hospitalization,
along with poor adherence of these patients to hygienic
measures as compared with non-dementia patients.
To conclude, we found frequent colonization with resis-
tant organisms among LTCF residents and staff, and much
lower rates in acute-care geriatric units. This difference can
probably be explained by different risk factors. Patients
transferred from the LTCF to acute-care hospitals should be
considered to be at high risk of carrying resistant organisms
and should be screened on admission. Screening should
include a rectal swab and a urine sample for ESBL and MBL
producers, and inguinal and oropharyngeal (not just nasal)
swabs for MRSA. Because LTCFs are also homes, hospital
infection control guidelines are unrealistic, but education of
the employees, improvement of hand hygiene, necessary use
of gloves and gowns, monitoring of diseases and treatment
are all keys to better management, as is ongoing surveillance.
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